Cardiol Therapeutics Inc. is a clinical-stage company developing anti-fibrotic and anti-inflammatory therapies for heart diseases. While it boasts a strong liquidity position with a current ratio of 3.89 and minimal debt (debt/equity of 0.01), its financial health is concerning due to negative returns on equity (-104.2%) and assets (-77.0%). The stock's recent decline of 1.20% may reflect investor apprehension regarding its profitability and the challenges of advancing clinical-stage products. Overall, while the company has a solid liquidity profile, its financial performance raises significant concerns.
Loading financial metrics...
Company has $11.6M in cash but burned $6.1M last quarter. At this burn rate, only 1.9 quarters of runway remain without additional financing.
Company posted a loss of $-34.8M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $24.2M over the last year.
Fortress balance sheet: cash covers total debt 87×, providing significant financial flexibility.
Excellent liquidity with current ratio of 3.9x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q3 (September 30, 2025)